624 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

    1. Sandra Ciesek. (2021, December 8). Unsere ersten Daten zur Neutralisation von Omicron versus Delta sind fertig: 2x Biontech, 2x Moderna, 1xAZ/1x Biontech nach 6 Monaten 0% Neutralisation bei Omicron, auch 3x Biontech 3 Monate nach Booster nur 25% NT versus 95% bei Delta. Bis zu 37fache Reduktion Delta vs. Omicron https://t.co/w0gHww26sg [Tweet]. @CiesekSandra. https://twitter.com/CiesekSandra/status/1468465347519041539

    1. Collier, A. Y., Brown, C. M., Mcmahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J. L., Rowe, M., Sellers, D., Ahmad, K., Aguayo, R., Anioke, T., Gardner, S., Siamatu, M., Rivera, L. B., Hacker, M. R., Madoff, L. C., & Barouch, D. H. (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (p. 2021.10.18.21265113). https://doi.org/10.1101/2021.10.18.21265113

    1. Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Gupta, R. K. (2022). Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature, 1–1. https://doi.org/10.1038/s41586-022-04474-x

    1. Vöhringer, H. S., Sanderson, T., Sinnott, M., De Maio, N., Nguyen, T., Goater, R., Schwach, F., Harrison, I., Hellewell, J., Ariani, C. V., Gonçalves, S., Jackson, D. K., Johnston, I., Jung, A. W., Saint, C., Sillitoe, J., Suciu, M., Goldman, N., Panovska-Griffiths, J., … Gerstung, M. (2021). Genomic reconstruction of the SARS-CoV-2 epidemic in England. Nature, 1–11. https://doi.org/10.1038/s41586-021-04069-y

    1. Kai Kupferschmidt. (2021, December 10). “the severity profile of Omicron cases must be interpreted along with an understanding of its capacity to re-infect (and infect the vaccinated)“ This is what I have been trying to explain the last few days. As usual @nataliexdean does it better (and in color)! [Tweet]. @kakape. https://twitter.com/kakape/status/1469270407995867139

    1. ReconfigBehSci. (2021, November 26). vaccine equity has been a disaster, but I do wonder whether the exclusive focus on donations does the US/EU comparison justice. The EU allowed the export of huge numbers of EU produced doses at a time when the US did not (and EU itself was struggling to meet demand). [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1464255575416520749

    1. ReconfigBehSci. (2021, November 26). maybe this is a good moment to remind people that makers of mRNA vaccines have been extensively prepping for the possibility of new variants. Biontech/Pfizer have given a timeline of 100 days to the delivery of a retooled version of their vaccine [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1464225264523747359

    1. John Burn-Murdoch. (2021, November 25). Five quick tweets on the new variant B.1.1.529 Caveat first: Data here is very preliminary, so everything could change. Nonetheless, better safe than sorry. 1) Based on the data we have, this variant is out-competing others far faster than Beta and even Delta did 🚩🚩 https://t.co/R2Ac4e4N6s [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1463956686075580421

    1. ReconfigBehSci. (2021, December 9). a rather worrying development- a (local) newspaper “fact checking” the new German health minister simply by interviewing a virologist who happens to have a different view. There’s simply no established “fact” as to the severity of omicron in children at this point in time [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1469037817481334786

  2. Jun 2022
    1. whole-genome sequencing (WGS) provides the highest possible subtyping resolution improving the surveillance, outbreak investigation, source attribution, and microbial population studies

      Purpose of WGS in population epidemiology

      1. Surveillance
      2. Outbreak Investigation
      3. Source attribution
      4. Microbial population
  3. Apr 2022
    1. Shalin Naik [@shalinhnaik]. (2021, October 14). 📢The first episode of the @thejabgab http://thejabgab.com is LIVE!! 🎙 Join me and the fabulous comedians @nazeem_hussain and @calbo as they chat about the Delta variant, vaccines …. And cows? With experts @DrKGregorevic and @BedouiSammy! Search your fav platform or... Https://t.co/bo4HiRfqF6 [Tweet]. Twitter. https://twitter.com/shalinhnaik/status/1448510610837159939

    2. Shalin Naik. (2021, October 14). 📢The first episode of the @thejabgab http://thejabgab.com is LIVE!! 🎙 Join me and the fabulous comedians @nazeem_hussain and @calbo as they chat about the Delta variant, vaccines …. And cows? With experts @DrKGregorevic and @BedouiSammy! Search your fav platform or... Https://t.co/bo4HiRfqF6 [Tweet]. @shalinhnaik. https://twitter.com/shalinhnaik/status/1448510610837159939

    1. Dr Dominic Pimenta [@DrDomPimenta]. (2021, December 15). An illustration of communicating risk with “less severe” variants: [Thread] Assume Omicron is 4x more transmissible than Delta. [1] Assume Omicron leads to 1/3 less admissions than Delta. [Figure below] Assume 1 in 100 cases of Delta are admitted to hospital. Https://t.co/XtnVwoOrUo [Tweet]. Twitter. https://twitter.com/DrDomPimenta/status/1471094002808242177

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. Carl T. Bergstrom. (2021, August 18). 1. There has been lots of talk about recent data from Israel that seem to suggest a decline in vaccine efficacy against severe disease due to Delta, waning protection, or both. This may have even been a motivation for Biden’s announcement that the US would be adopting boosters. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1427767356600688646

    1. Eric Topol. (2021, June 9). Despite increasing incentives, the US vaccination campaign is really struggling. Notably, the top 5 states are approaching 60% total population fully vaccinated which should provide strong protection vs the delta variant. A different story for the bottom 5 states @OurWorldInData https://t.co/boqk3Khhuc [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1402413221667954690

    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Alessandro Vespignani. (2021, April 14). “Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil”—P.1 may be 1.7–2.4-fold more transmissible—Previous (non-P.1) infection provides 54–79% of the protection against infection with P.1 that it provides against non-P.1 lineages https://t.co/aUpL4YOFYo https://t.co/YniaLb9YiF [Tweet]. @alexvespi. https://twitter.com/alexvespi/status/1382370044374511621

    1. Prof. Christina Pagel. (2021, May 3). THREAD: Update on B.1.617 (‘India’) variant in England using latest data from the Sanger institute. This data excludes sequenced cases from travellers & surge testing so ‘should be an approximately random sample of positive tests in the community’ TLDR: warning signs! 1/10 https://t.co/0UzhM8GNIA [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1389273187586875396

    1. Denise Dewald, MD 🗽. (2021, August 12). Here are some modeling predictions for the delta variant from COVSIM (group at North Carolina State): PLEASE CHECK THIS OUT - RESOURCES TO SHARE WITH YOUR SCHOOL DISTRICT School-level COVID-19 Modeling Results for North Carolina for #DeltaVariant https://t.co/zU5hB9bKlY [Tweet]. @denise_dewald. https://twitter.com/denise_dewald/status/1425626289399009288

    1. Marc Lipsitch. (2021, July 20). At the risk of boiling down too much and certainly losing some detail, one way to summarize this wonderful thread is that when we think about vaccine effectiveness, we should think of 4 key variables: 1 which vaccine, 2 age of the person, 3 how long after vax, 4 vs what outcome. [Tweet]. @mlipsitch. https://twitter.com/mlipsitch/status/1417595538632060931

    1. Prof. Christina Pagel 🇺🇦. (2021, November 25). THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today TLDR: So much uncertain but what is known is extremely worrying & (in my opinion) we should revise red list immediately. This is why: 1/16 [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1463885539619311616

    1. Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Bertollini, R. (2022). Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar (p. 2022.01.18.22269452). medRxiv. https://doi.org/10.1101/2022.01.18.22269452

    1. Prof. Shane Crotty. (2021, December 8). 3 studies today on antibodies & Omicron. 🔵 There may be a large drop in neutralization of Omicron 🔵 Antibodies stop Omicron well in hybrid immunity (infected+vax) 🔵 Sotrovimab is active versus Omicron Take home: Get vaccinated. Get boosted. Immune system is clever. 🧵 1/n [Tweet]. @profshanecrotty. https://twitter.com/profshanecrotty/status/1468390479280574472

  4. Mar 2022
    1. Mia Malan. (2021, November 25). [Thread] What is the potential impact of the new B.1.1.529 #COVID19 variant? @rjlessells: 1. It’s relatively simple to detect some B.1.1.529 cases, as it’s possible to use PCR tests to do this in some cases 2. B.1.1.529 = has many mutations across different parts of the virus https://t.co/ytktqLzJUi [Tweet]. @miamalan. https://twitter.com/miamalan/status/1463846528578109444

  5. Feb 2022
    1. Marc Stegger. (2022, February 22). New preprint on #COVID19 is out: “Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection”. Using the national surveillance system in Denmark, we show that reinfections with #SARSCoV2 VOC #Omicron BA.2 can occur after recent BA.1 infection #SSI_dk https://t.co/Cm0n8vga4P [Tweet]. @MarcStegger. https://twitter.com/MarcStegger/status/1496099303143653379

    1. Kok, K.-H., Wong, S.-C., Chan, W.-M., Lei, W., Chu, A. W.-H., Ip, J. D., Lee, L.-K., Wong, I. T.-F., Lo, H. W.-H., Cheng, V. C.-C., Ho, A. Y.-M., Lam, B. H.-S., Tse, H., Lung, D., Ng, K. H.-L., Au, A. K.-W., Siu, G. K.-H., & Yuen, K.-Y. (2022). Cocirculation of two SARS-CoV-2 variant strains within imported pet hamsters in Hong Kong. Emerging Microbes & Infections, 1–39. https://doi.org/10.1080/22221751.2022.2040922

    1. Stegger, M., Edslev, S. M., Sieber, R. N., Ingham, A. C., Ng, K. L., Tang, M.-H. E., Alexandersen, S., Fonager, J., Legarth, R., Utko, M., Wilkowski, B., Gunalan, V., Bennedbæk, M., Byberg-Grauholm, J., Møller, C. H., Christiansen, L. E., Svarrer, C. W., Ellegaard, K., Baig, S., … Rasmussen, M. (2022). Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection (p. 2022.02.19.22271112). medRxiv. https://doi.org/10.1101/2022.02.19.22271112

    1. Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., Lee, G. S., Choi, S. K., Takhar, H. S., Aragones, M., & Qian, L. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine, 1–1. https://doi.org/10.1038/s41591-022-01753-y

    1. Cornelius Roemer. (2022, February 12). Fantastic work by @UKHSA comparing serial intervals of BA.1, BA.2 and Delta as published in the most recent technical briefing. BA.2 seems to have even shorter serial interval than BA.1 This could help explain different relative growth rates of BA.2 vs BA.1 in different countries https://t.co/Gch94Ew8CX [Tweet]. @CorneliusRoemer. https://twitter.com/CorneliusRoemer/status/1492434232664375304

    1. Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Abu-Raddad, L. J. (2022). Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2200133

    1. Ali Ellebedy. (2021, December 30). We need those who are adept at #SciComm to explain that “Omicron” is sufficiently different from the original strain that was used to make the vaccine. Therefore, the definition of “fully vaccinated” will have to be updated, but that does not mean that the vaccines have failed. [Tweet]. @TheBcellArtist. https://twitter.com/TheBcellArtist/status/1476649138691444740

    1. Ulrich Elling. (2022, January 12). While #Omicron BA.1 leads the race, the little sister BA.2 is catching up in numbers. They are rather different with likely functional implications. BA.2 might be more immune evasive in RBD, less in NTD. And due to reduced mutation load in NTD maybe different fusion properties? Https://t.co/kEACjzQDs3 [Tweet]. @EllingUlrich. https://twitter.com/EllingUlrich/status/1481214901997682692

    1. Jonathan Li on Twitter: “There’s a lineage of Omicron that’s gained the R346K mutation (BA.1.1). This one could spell some trouble for the AZ mAb (tixagevimab/cilgavimab, Evusheld) that’s being used for pre-exposure prophylaxis. If you want to learn about tix/cil vs Omicron, read on 1/7” / Twitter. (n.d.). Retrieved February 6, 2022, from https://twitter.com/DrJLi/status/1487479972293853188

    1. Prof. Christina Pagel. (2022, January 31). Update on growth of Omicron subvariant BA.2 in England from Wellcome Sanger data. Growing in all regions. The main Omicron variant we’ve had so far is BA.1. There is then its child BA.1.1 with an extra mutation and its brother BA.2 which is pretty different to BA.1. 1/2 https://t.co/iVxrf01P4o [Tweet]. @chrischirp. https://twitter.com/chrischirp/status/1488127760291799041

  6. Jan 2022
    1. Tom Wenseleers. (2022, January 30). Seems that the second Omicron subvariant BA.2 may soon be about to cause cases to start rising again in South Africa... Or at least to stop the decline in new infections. Shows how fast immunity wanes & evolution can catch up. Https://t.co/3y4xqPgZ0L [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1487919837670219781

    1. Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.-V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2119912

    1. Elliott, P., Eales, O., Bodinier, B., Tang, D., Wang, H., Jonnerby, J., Haw, D., Elliott, J., Whitaker, M., Walters, C., Atchison, C., Diggle, P., Page, A., Trotter, A., Ashby, D., Barclay, W., Taylor, G., Ward, H., Darzi, A., … Donnelly, C. (2022). Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 [Working Paper]. http://spiral.imperial.ac.uk/handle/10044/1/93887